Company Profile

Ibis Biosciences Inc (AKA: Ibis Technologies)
Profile last edited on: 4/10/19      CAGE: 4NSH6      UEI:

Business Identifier: Identification and characterization of infectious agents
Year Founded
2006
First Award
2004
Latest Award
2011
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1896 Rutherford Road
Carlsbad, CA 92008
   (760) 476-3301
   info@ibisbio.com
   www.ibisbiosciences.com
Location: Single
Congr. District: 49
County: San Diego

Public Profile

In December 2008, Ibis Biosciences was acquired by Abbott Laboratories from which point, the firm is now operating as a subsiduary of Abbott Moclualr. Previous doing business as Ibis Technologies, the firm is organized around working on products for the identification and characterization of infectious agents, Ibis Biosciences had been a wholly owned subsidiary of Isis Pharmaceuticals. Ibis Biosciences has developed the Ibis T5000 Biosensor System, a hardware platform, and accompanying research assay kits, that have the potential to revolutionize the identification of infectious diseases. Ibis Biosciences employs a unique solution for the identification of biological organisms, including bacteria, viruses, fungi, and protozoa. It is also a powerful tool for human forensics

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
100-149

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 2 NIH $3,106,479
Project Title: Broad Detection System For Tick-Borne Pathogens
2009 2 NIH $838,950
Project Title: Single Well MPCR Donor Screen to ID Blood Pathogens
2009 2 NIH $849,941
Project Title: Rapid High-Throughput Mycobacterium Tuberculosis Genotyping
2009 2 NIH $886,425
Project Title: HCV Genotyping and Drug Resistance Testing by ESI/MS

Key People / Management

  Michael Treble -- President

  Lawrence B Blyn

  David J Ecker -- Founder and Chief Scientific Officer

  Mark W Eshoo

  Christian Massire

Company News

There are no news available.